OBJECTIVE: The purpose of this study was (a) to study whether a folate and vitamin B12 treatment, aimed at decreasing homocysteine levels, might ameliorate insulin resistance and endothelial dysfunction in patients with metabolic syndrome according to the National Cholesterol Education Program-Adult Treatment Panel-III criteria and (b) to evaluate whether, under these metabolic conditions, there is a relationship between hyperhomocysteinemia and insulin resistance. DESIGN AND METHODS: A double-blind, parallel, identical placebo-drug, randomized study was performed for 2 months in 50 patients. Patients were randomly allocated to two groups. In group 1, patients were treated with diet plus placebo for 2 months. In group 2, patients were treated with diet plus placebo for 1 month, followed by diet plus folic acid (5 mg/day) plus vitamin B12 (500 microg/day) for another month. RESULTS: In group 2, folate treatment significantly decreased homocysteine levels by 27.8% (12.2+/-1.2 vs 8.8+/-0.7 micromol/l; P<0.01). A significant decrement was observed for insulin levels (19.9+/-1.7 vs 14.8+/-1.6 microU/ml; P<0.01) accompanied by a 27% reduction in the homeostasis model assessment levels. A positive relationship was found between the decrement of homocysteine and insulin levels (r=0.60; P<0.002). In parallel, endothelial dysfunction significantly improved in the treated group, since post-ischemic maximal hyperemic vasodilation increased by 29.8% and cGMP by 13.6% while asymmetrical dimethylarginine levels decreased by 21.7%. On the contrary, in group 1 patients, treated with placebo, no changes were shown in any of the variables. CONCLUSIONS:Folate and vitamin B12 treatment improved insulin resistance and endothelial dysfunction, along with decreasing homocysteine levels, in patients with metabolic syndrome, suggesting that folic acid has several beneficial effects on cardiovascular disease risk factors.
RCT Entities:
OBJECTIVE: The purpose of this study was (a) to study whether a folate and vitamin B12 treatment, aimed at decreasing homocysteine levels, might ameliorate insulin resistance and endothelial dysfunction in patients with metabolic syndrome according to the National Cholesterol Education Program-Adult Treatment Panel-III criteria and (b) to evaluate whether, under these metabolic conditions, there is a relationship between hyperhomocysteinemia and insulin resistance. DESIGN AND METHODS: A double-blind, parallel, identical placebo-drug, randomized study was performed for 2 months in 50 patients. Patients were randomly allocated to two groups. In group 1, patients were treated with diet plus placebo for 2 months. In group 2, patients were treated with diet plus placebo for 1 month, followed by diet plus folic acid (5 mg/day) plus vitamin B12 (500 microg/day) for another month. RESULTS: In group 2, folate treatment significantly decreased homocysteine levels by 27.8% (12.2+/-1.2 vs 8.8+/-0.7 micromol/l; P<0.01). A significant decrement was observed for insulin levels (19.9+/-1.7 vs 14.8+/-1.6 microU/ml; P<0.01) accompanied by a 27% reduction in the homeostasis model assessment levels. A positive relationship was found between the decrement of homocysteine and insulin levels (r=0.60; P<0.002). In parallel, endothelial dysfunction significantly improved in the treated group, since post-ischemic maximal hyperemic vasodilation increased by 29.8% and cGMP by 13.6% while asymmetrical dimethylarginine levels decreased by 21.7%. On the contrary, in group 1 patients, treated with placebo, no changes were shown in any of the variables. CONCLUSIONS:Folate and vitamin B12 treatment improved insulin resistance and endothelial dysfunction, along with decreasing homocysteine levels, in patients with metabolic syndrome, suggesting that folic acid has several beneficial effects on cardiovascular disease risk factors.
Authors: Julia H Kreznar; Mark P Keller; Lindsay L Traeger; Mary E Rabaglia; Kathryn L Schueler; Donald S Stapleton; Wen Zhao; Eugenio I Vivas; Brian S Yandell; Aimee Teo Broman; Bruno Hagenbuch; Alan D Attie; Federico E Rey Journal: Cell Rep Date: 2017-02-14 Impact factor: 9.423
Authors: Gideon R Hajer; Yolanda van der Graaf; Jobien K Olijhoek; Marianne C Verhaar; Frank L J Visseren Journal: Heart Date: 2006-09-04 Impact factor: 5.994
Authors: Eva-Maria Navarrete-Muñoz; Jesus Vioque; Estefanía Toledo; Alejando Oncina-Canovas; Miguel Ángel Martínez-González; Jordi Salas-Salvadó; Dolores Corella; Montserrat Fitó; Dora Romaguera; Ángel M Alonso-Gómez; Julia Wärnberg; J Alfredo Martínez; Luís Serra-Majem; Ramon Estruch; Francisco J Tinahones; José Lapetra; Xavier Pintó; Josep A Tur; José López-Miranda; Aurora Bueno-Cavanillas; Pilar Matía-Martín; Lidia Daimiel; Vicente Martín Sánchez; Josep Vidal; Ana Isabel de Cos Blanco; Emili Ros; Javier Diez-Espino; Nancy Babio; Rebeca Fernandez-Carrion; Olga Castañer; Antoni Colom; Laura Compañ-Gabucio; Itziar Salaverria Lete; Edelys Crespo-Oliva; Itziar Abete; Laura Tomaino; Rosa Casas; José Carlos Fernandez-Garcia; José Manuel Santos-Lozano; Iziar Sarasa; José M Gámez; José M Antonio Garcia-Rios; Sandra Martín-Pelaez; Miguel Ruiz-Canela; Andrés Díaz-López; Raul Martinez-Lacruz; Maria Dolors Zomeño; Elena Rayó; Cristina Gisbert Sellés; Silvia Canudas; Albert Goday; Manoli García-de-la-Hera Journal: Eur J Nutr Date: 2020-08-24 Impact factor: 5.614
Authors: Vicki L Ellingrod; Del D Miller; Stephan F Taylor; Jessica Moline; Timothy Holman; Jane Kerr Journal: Schizophr Res Date: 2007-10-31 Impact factor: 4.939
Authors: O Cigerli; H Parildar; A Dogruk Unal; O Tarcin; A Kut; H Eroglu; N Guvener Journal: Acta Endocrinol (Buchar) Date: 2016 Jul-Sep Impact factor: 0.877
Authors: Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas Journal: Arthritis Res Ther Date: 2009-07-16 Impact factor: 5.156